PVLA

142.8502.00%
TC

Todd C. Davis

Independent Director

Mr. Todd C. Davis, Ph.D. is Independent Director of Palvella Therapeutics, Inc. from December 2024. He is Chief Executive Officer at Ligand Pharmaceuticals Incorporated since December 05, 2022. He is Director of XOMA Royalty Corporation from July 14, 2026. He served as Independent Chairman of the Board of Vaxart, Inc. since July 2021 until March 2023. He has served as the Founder, Managing Partner and President of RoyaltyRx Capital, LLC, special opportunities investment firm focused on pharmaceuticals, since January 2018. He has been a Director of Vaxart, Inc. since October 25, 2019. He is Director of ViroCell Biologics. Mr. Davis has been a Director of BioDelivery Sciences International, Inc. since May 21, 2018. He serves as a Managing Director at Cowen Group, Inc. He co-funded Cowen/Healthcare Royalty Partners in January 2007 and was its Founding Managing Director and Managing Partner from 2007 to December 2017. From 2006 to 2018, Mr. Davis was a founder and managing partner of Cowen/HealthCare Royalty Partners, a global healthcare investment firm. November 2019, he has also served as Chairman and Chief Executive Officer of Benuvia Holdings Inc. a pharmaceutical holding company. He served as Managing Director at Suneva Medical, Inc. He was a Partner at Paul Capital Partners, where he co-managed that firm's royalty investments from 2004 to 2006. He was responsible for sourcing and evaluating royalty and revenue-interest investment opportunities in the United States. He focused primarily on United States biopharmaceutical investments and led investment efforts in public companies and private companies, as well as equity, debt and royalty structures within that arena. He has led, structured and closed over 40 additional intellectual property licenses, as well as growth equity and debt deals. He has played a pivotal role in sourcing, evaluating and negotiating United States life science investment opportunities. He was a Partner of healthcare team at Apax Partners LLP from 2001 to 2004. He served as the Vice President of Global Licensing and Business Development at Elan Drug Delivery. In this role, he was responsible for all business aspects of EElan Pharmaceuticals' drug delivery technologies including clinical marketing, licensing and product development. Prior to beginning his Principal investment career in 2001, Mr. Davis was at Abbott Laboratories as a Product Manager for Diagnostic Automation Systems and worked in field of sales and was also in the launch team for several breakthrough diagnostic products. He served as Chairman of Suneva Medical, Inc. since August 4, 2016 until November 9, 2017. He served as Vice Chairman of Suneva Medical, Inc. until August 4, 2016. He was on Board at TearScience from February 2016 to October 2017. He served as Chairman of the Board of Helomics Corporation and served as Director since November 2014 to June 2017. He served on the Board of AcuFocus from April 2017 to December 2017 and Artes Medical, Inc. from January 2008 to December 2008. He has been an Independent Director at Ligand Pharmaceuticals Incorporated since March 1, 2007 and was Director of Palvella Therapeutics Inc. since June 2017. He is Director of Shore Therapeutics, Nuron Biotech. He served as Director at Suneva Medical, Inc. from January 2009 until November 9, 2017. He served as a Director of Sheffield Pharmaceuticals, Verus Pharmaceuticals, Prism Pharmaceuticals, Prometheus Laboratories, Sensys Medical Inc. and SkinMedica, Inc. He served as an Officer in the United States Navy, initially as a Naval Aviator and subsequently in the surface fleet. He has expertise in the commercial, operational and licensing aspects of potential investments. Mr. Davis has worked in marketing, operational management and technology licensing. He also is a Board Member of the Harvard Business School Healthcare Alumni Association. He has a global reach and deep work in commercializing healthcare technologies. Mr. Davis has earned an M.B.A. from the Harvard Business School and a BS from the United States Naval Academy at Annapolis. He is Director of Pelthos Therapeutics Inc. Mr. Davis was Chairman of the Board of Pelthos Therapeutics Inc. until July 1, 2025.

Positions